Cargando…

Antifibrinolytics in a rural trauma state: assessing the opportunities

BACKGROUND: Tranexamic acid (TXA) has demonstrated improved mortality among trauma patients. However, recent evidence from urban US trauma centers has failed to show a benefit among the civilian population. TXA in rural states has not been evaluated. This study aimed to evaluate the current use of T...

Descripción completa

Detalles Bibliográficos
Autores principales: Bardes, James M, Palmer, Amanda, Con, Jorge, Wilson, Alison, Schaefer, Gregory
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877915/
https://www.ncbi.nlm.nih.gov/pubmed/29766102
http://dx.doi.org/10.1136/tsaco-2017-000107
_version_ 1783310790417186816
author Bardes, James M
Palmer, Amanda
Con, Jorge
Wilson, Alison
Schaefer, Gregory
author_facet Bardes, James M
Palmer, Amanda
Con, Jorge
Wilson, Alison
Schaefer, Gregory
author_sort Bardes, James M
collection PubMed
description BACKGROUND: Tranexamic acid (TXA) has demonstrated improved mortality among trauma patients. However, recent evidence from urban US trauma centers has failed to show a benefit among the civilian population. TXA in rural states has not been evaluated. This study aimed to evaluate the current use of TXA in the rural trauma population. METHODS: A retrospective observational review at a level 1 trauma center based in a rural environment. Records were reviewed for TXA indications. TXA indication was defined as: systolic blood pressure <90 mm Hg, blood transfusion, or with a clinical concern for ongoing bleeding. Patients were ineligible if the time since injury was >3 hours. RESULTS: 400 patients were evaluated. 54% of patients met indications for TXA. 14% of these received TXA. 30.4% with an indication for TXA were ineligible due to arrival beyond 3 hours from time of injury. 135 patients arrived as transfers, 265 from the scene. There was no difference in TXA indications between scene and transfers (73 vs 144, p=1). Transfers were more likely to arrive beyond the 3-hour window (59 vs 7, p=0.001). Mortality for patients treated with TXA was 12.5%. This was not significantly different from patients not treated with TXA (19%). DISCUSSION: In a rural system, long transfers exclude most patients from treatment with TXA. A multicenter rural trauma center study will be needed to better define the optimal use of TXA in rural populations. LEVEL OF EVIDENCE: Level IV data: therapeutic/care management.
format Online
Article
Text
id pubmed-5877915
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-58779152018-05-14 Antifibrinolytics in a rural trauma state: assessing the opportunities Bardes, James M Palmer, Amanda Con, Jorge Wilson, Alison Schaefer, Gregory Trauma Surg Acute Care Open Original Article BACKGROUND: Tranexamic acid (TXA) has demonstrated improved mortality among trauma patients. However, recent evidence from urban US trauma centers has failed to show a benefit among the civilian population. TXA in rural states has not been evaluated. This study aimed to evaluate the current use of TXA in the rural trauma population. METHODS: A retrospective observational review at a level 1 trauma center based in a rural environment. Records were reviewed for TXA indications. TXA indication was defined as: systolic blood pressure <90 mm Hg, blood transfusion, or with a clinical concern for ongoing bleeding. Patients were ineligible if the time since injury was >3 hours. RESULTS: 400 patients were evaluated. 54% of patients met indications for TXA. 14% of these received TXA. 30.4% with an indication for TXA were ineligible due to arrival beyond 3 hours from time of injury. 135 patients arrived as transfers, 265 from the scene. There was no difference in TXA indications between scene and transfers (73 vs 144, p=1). Transfers were more likely to arrive beyond the 3-hour window (59 vs 7, p=0.001). Mortality for patients treated with TXA was 12.5%. This was not significantly different from patients not treated with TXA (19%). DISCUSSION: In a rural system, long transfers exclude most patients from treatment with TXA. A multicenter rural trauma center study will be needed to better define the optimal use of TXA in rural populations. LEVEL OF EVIDENCE: Level IV data: therapeutic/care management. BMJ Publishing Group 2017-10-05 /pmc/articles/PMC5877915/ /pubmed/29766102 http://dx.doi.org/10.1136/tsaco-2017-000107 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Original Article
Bardes, James M
Palmer, Amanda
Con, Jorge
Wilson, Alison
Schaefer, Gregory
Antifibrinolytics in a rural trauma state: assessing the opportunities
title Antifibrinolytics in a rural trauma state: assessing the opportunities
title_full Antifibrinolytics in a rural trauma state: assessing the opportunities
title_fullStr Antifibrinolytics in a rural trauma state: assessing the opportunities
title_full_unstemmed Antifibrinolytics in a rural trauma state: assessing the opportunities
title_short Antifibrinolytics in a rural trauma state: assessing the opportunities
title_sort antifibrinolytics in a rural trauma state: assessing the opportunities
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877915/
https://www.ncbi.nlm.nih.gov/pubmed/29766102
http://dx.doi.org/10.1136/tsaco-2017-000107
work_keys_str_mv AT bardesjamesm antifibrinolyticsinaruraltraumastateassessingtheopportunities
AT palmeramanda antifibrinolyticsinaruraltraumastateassessingtheopportunities
AT conjorge antifibrinolyticsinaruraltraumastateassessingtheopportunities
AT wilsonalison antifibrinolyticsinaruraltraumastateassessingtheopportunities
AT schaefergregory antifibrinolyticsinaruraltraumastateassessingtheopportunities